Navigation Links
Combination vaccine protects monkeys from ebola and Marburg viruses
Date:2/26/2008

An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results today (Feb. 26) at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.

VLPs are one of the most promising candidates for protecting humans against Ebola and Marburg virus infections, says Dr. Kelly Warfield, a researcher at USAMRIID who presented the study. They could also be safer than other vaccine candidates.

Traditionally vaccines against viral diseases have consisted of whole viruses, either the one that causes the disease in a weakened or dead state (like the polio vaccine) or a genetically similar virus that does not usually cause disease but elicits a protective immune response. The problem with this approach is there is the risk, however small, of viral reactivation and infection.

Since the VLP vaccine does not use a whole virus, there is no chance of infection, says Warfield, who notes that some VLP-based vaccines, such as the human papillomavirus (HPV) vaccine, are already on the market.

To create the vaccine, Warfield and her colleagues infected insect cells with specially engineered baculoviruses. The infected cells then produced VLPs for either Marburg or Ebola, depending on the baculovirus, which were then purified. They mixed the two together and vaccinated the monkeys with it.

Following challenge with Ebola or Marburg virus, all the VLP-vaccinated monkeys survived challenge without clinical or laboratory signs of infection, while the control animals succumbed to the infection, says Warfield. Based on their safety profile, immunogenicity and protective efficacy, the VLPs are a leading candidate for use as a filovirus vaccine in humans.

Additionally, Warfield discovered that vaccinatio
'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology technology :

1. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
4. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
5. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
7. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
10. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth ... the Renaissance Waterfront Hotel in Boston, MA. The ... at the current strategies and innovations for optimizing bioprocesses ... in the field will reveal how their work has ... specificity and efficiency. , “In this age of rapid ...
(Date:5/16/2013)...  The registration deadline has been extended until May ... National Conference, the premier conference for bioscience financial officers. ... Hilton San Diego Bayfront. "We are ... want to make sure as many people as possible ... Roberts , Chief Financial Officer of Mast Therapeutics, ...
(Date:5/16/2013)... On average, developing a new drug takes over ... this investment, less than 10% of drugs make it ... trial design optimally structured to balance time, cost and ... Sax, Global Head of the Center for Drug Development ... and technology in upfront clinical trial planning and design ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Oct. 27 Soligenix, Inc., (Soligenix or the Company) ... Inc., a late-stage biotechnology company, announced today that its ... overview highlighting recent developments at the BIO Investor Forum. ... 29, 2009 at 1:00 PM PDT at The Palace ...
... does a university introduce a cutting-edge academic model, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/NY99197LOGO ) , By ... required attendance) -- all in a first-year forum ... , Polytechnic Institute of New York University,s newest ...
... , Inc. (AIM: CRW.L), a leader in financial ... presentation at the Healthcare Financial Management Association,s (HFMA) Revenue ... IL. The session will be led by an industry ... of Revenue Integrity, Wendi Accardi of Advocate Health Care, ...
Cached Biology Technology:Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 2NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 3NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 4Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 2Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Endocrine Society (ENDO) 95th Annual Meeting in ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the ENDO 2013 Annual Meeting. , Awards are ...
(Date:5/16/2013)... have used ancient shorelines to predict the stability of today,s ... high shoreline from three million years ago, for example ... thought to be evidence of a high sea level due ... led many scientists to think that if the world,s largest ... just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... the cellular layer lining the body,s blood vessels, ... nanometers in thickness, this super-tenuous structure routinely withstands ... to create a unique and highly dynamic barrier ... from the body,s circulatory system. , It,s also ... be physically breached to enable immune cells ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the largest baby boom ever documented for the stock, with ... With typical annual averages of 50 to 100 million new ... puzzled by the huge increase and its ramifications for stock ... found one - healthy adults. In a study to ...
... technology, researchers led by a Weill Cornell Medical College scientist ... about half of all prostate cancers. Estrogen-linked signaling helps ... by a chromosomal translocation, which in turn results in the ... cancers harbor a common recurrent gene fusion, and we believe ...
... discovered that a fundamental building block in the ... identically, on a separate branch of the evolutionary ... originated at least 420 million years ago. ... gymnosperms, the group that includes conifers, ginkgos and ...
Cached Biology News:Healthy parents provide clues to survival of young haddock on Georges Bank 2Estrogen helps drive distinct, aggressive form of prostate cancer 2Estrogen helps drive distinct, aggressive form of prostate cancer 3When plants 'think' alike 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Biology Products: